ShortCV Prof.Dr.med.SamerEzziddin,MSc 05/2018

SamerEzziddin,MSc,MD,PhD• ProfessorofNuclearMedicineatSaarlandUniversity• Director,Dep.NuclearMedicine,SaarlandUniversityHospital•MDUSA(ECFMGcertified;USMLEStep1-2,CSAPhiladelphia)•MasterofScienceinMedicalDevicesClinicalTechnology(MSc)

• CommitmentsinCommitteesandTaskGroups(excerpt)o TherapyCommittee,EuropeanAssociationofNuclearMedicineo JointCommitteeforInternalDosimetry(EANM)o CIRTSteeringCommittee,SIRTRegistry(CIRSE)o NationalExpertPanelforRadioembolization(SIRTranet)o GuidelinesCommittee,GermanSocietyofNuclearMedicine(DGN)o TherapyPanel/WorkingGroup(DGN)

• Coauthorofvariousguidelines,focus:TheranosticsinOncology• >100publishedscientificarticlesinpeer-reviewedjournals,EditorialBoardMemberofvariousscientificjournals

AftergraduationfromMedicalSchool inFrankfurta.M./Germany in1997,SamerEzziddinwentontoaone-year residency inMedicine and Endocrinology at the University of Cologne. He passed the USMLEincludingtheClinicalSkillsAssessmentinPhiladelphia/MA,andachievedfullECFMGcertificationin1999.During his residency and subsequent time as Assistant Medical Director in Nuclear Medicine at theUniversity of Bonnhe introduced 177Lu-based peptide receptor radionuclide therapy (PRRT) in 2004 anddevelopedthetargetedtherapyprogram.AfteranexternshipinInterventionalOncologyatNorthwesternUniversity / Chicago (Prof. Salem), he restructured and expanded the Radioembolization routine at hisinstitutionduringhisDeputyDirectorperiodinBonn(2008-2014),achievingthefirstEuropeandual-licenseforResinandGlassMicrosphereRadioembolization,andintroducedintra-arterialPRRT.HisGermanPhD(Habilitation) inNuclearMedicine focusedonoutcomepredictors inPRRT.He isawell-recognized international expert on neuroendocrine tumors and targeted radionuclide therapy and hasextensively published in the area of dosimetry and molecular imaging for planning and monitoringradioembolization(SIRT).ThemasterthesisofhisaccompanyingstudiesinMedicalDeviceClinicalSciences(MSc)attheUniversityofBonnaddressedthedifferentimpactofradioembolizationdevices.Otherfieldsofexpertiseandactivitiesinvolvethyroid&prostatecancerandmultimodalityimaging(PET-CT,SPECT-CT).SamerEzziddinhascontributedtovariousguidelinesandtaskgroupsincludingcommitmentsasmemberofthe Radionuclide Therapy Committee of the European Association of Nuclear Medicine (EANM), theTherapy Committee and Guideline Committee of the German Society of Nuclear Medicine (DGN), theNationalExpertGroupforRadioembolization(SIRTranet)andtheSteeringCommitteefortheCIRSERegistryforSIR-MicrosphereTherapy(CIRT).SinceAugust2014ProfessorEzziddinisHeadoftheNuclearMedicineDepartment at Saarland University Hospital. With his therapeutic focus in oncology and devotion totargetedtreatmentheaimsatindividualizingandoptimizingradionuclide-basedtargetedtumortherapy.Underhisdirection,theUniversity-basedDep.ofNuclearMedicineinHomburgbecameoneoftheleadinginstitutionsworldwideinthefieldofmoleculartargetedradionuclidetherapyofadvancedtumors.